Emcure Pharmaceuticals Announces 45th AGM on Sep 21, 2026, Sets Record Date for Final Dividend
Emcure Pharmaceuticals will hold its 45th AGM on September 21, 2026. The record date for the final dividend of ₹3.60 per share for FY26 is set for September 04, 2026. Dividend payment is expected within 30 days of AGM approval.
The announcement concerns the Annual General Meeting and the record date for dividend payment, which are important for shareholders and indicate a step in the company's financial reporting and shareholder returns process.
The announcement is a routine intimation regarding the AGM date and record date for dividend payment, with no new financial performance data or significant strategic changes mentioned.
Emcure Pharmaceuticals Limited has announced that its 45th Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM) in compliance with applicable circulars.
The Board of Directors, in their meeting on May 05, 2026, had recommended a Final Dividend of ₹3.60 per equity share (36%) for the financial year ended March 31, 2026. The company has fixed Friday, September 04, 2026, as the Record Date to determine the entitlement of members for this Final Dividend. If approved at the AGM, the dividend payment will be made within 30 days of the AGM approval, subject to applicable tax deductions.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.